Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status and phase

Completed
Phase 3

Conditions

Impetigo

Treatments

Drug: SB-275833 ointment, 1%

Study type

Interventional

Funder types

Industry

Identifiers

NCT00133848
TOC103469

Details and patient eligibility

About

The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.

Sex

All

Ages

9+ months old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Must have primary impetigo with total lesion area being 100 square centimeters or less.
  • Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures.

Exclusion criteria

  • Any signs and symptoms of systemic infection.
  • Any serious underlying disease that could be imminently life threatening.

Trial contacts and locations

22

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems